SOURCE: Milestone Scientific, Inc.

Milestone Scientific

December 03, 2015 10:36 ET

Milestone Scientific's Epidural & Intra-Articular Subsidiary Presents Initial Results of Clinical Trials for Its Epidural Instrument at Event for Leading Anesthesiologists and Key Opinion Leaders

LIVINGSTON, NJ--(Marketwired - December 03, 2015) - Milestone Scientific's (NYSE MKT: MLSS) Epidural & Intra-Articular Subsidiary today announced that it hosted an event on November 20th in Miami, FL for a group of leading anesthesiologists and key opinion leaders in the field. Professor Ralf E. Gebhard, M.D., from the University of Miami, discussed the CompuFlo® technology and its areas of clinical application.

Dr. Gebhard also addressed the progress of the COMPASS clinical study, a randomized, controlled, parallel group, multicenter, pivotal study aimed at assessing the safety and effectiveness of epidural space verification with the CompuFlo® Epidural Computer Controlled System. The goal of the pivotal IDE clinical trial is to demonstrate the accuracy of Milestone's CompuFlo® technology in identifying and confirming the epidural space location as part of the US regulatory pathway.

Leonard Osser, Chief Executive Officer of Milestone Scientific added, "We believe our instrument has the potential to transform an industry that has been plagued with safety concerns with one of the highest rates of malpractice in medicine. We believe our instrument represents the future of painless, safe and effective epidural procedures."

About Milestone Scientific Inc.

Milestone Scientific Inc. (MLSS) is a medical R&D company that designs, patents, incubates and commercializes a growing portfolio of innovative injection technologies. Milestone's computer-controlled systems make injections precise, efficient, and virtually painless. For more information please visit our website: www.milestonescientific.com.

Safe Harbor Statement
This press release contains forward-looking statements regarding the timing and financial impact of Milestone's ability to implement its business plan, expected revenues and future success. These statements involve a number of risks and uncertainties and are based on assumptions involving judgments with respect to future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond Milestone's control. Some of the important factors that could cause actual results to differ materially from those indicated by the forward-looking statements are general economic conditions, failure to achieve expected revenue growth, changes in our operating expenses, adverse patent rulings, FDA or legal developments, competitive pressures, changes in customer and market requirements and standards, and the risk factors detailed from time to time in Milestone's periodic filings with the Securities and Exchange Commission, including without limitation, Milestone's Annual Report for the year ended December 31, 2014. The forward looking statements in this press release are based upon management's reasonable belief as of the date hereof. Milestone undertakes no obligation to revise or update publicly any forward-looking statements for any reason.

Contact Information

  • Contact:
    David Waldman or Natalya Rudman
    Crescendo Communications, LLC
    Email: mlss@crescendo-ir.com
    Tel: 212-671-1020